Fig. 1: Initial elucidation of the myeloma plasma cell surfaceome.
A Overall schematic of surface proteomic investigations in this study. This includes a description of the modified cell surface capture (CSC) methodology used, with biotinylated proteins identified after on-bead trypsinization. B Upset plot shows high degree of overlap in identified glycoproteins, filtered for annotated membrane proteins, across the four evaluated myeloma cell lines. Data included if identified with two peptides in at least one of three biological replicates per cell line. C Common myeloma diagnostic markers and immunotherapeutic targets were identified by cell surface proteomics in all four evaluated cell lines. Height of column indicates label-free quantification (LFQ) intensity from MaxQuant, averaged across biological replicate samples (AMO1: n = 3, L363: n = 2, KMS12: n = 3, RPMI-8226: n = 3). A threshold of LFQ = 25 is indicated by gray line. D Principal component analysis (PCA) illustrates the differential cell surface landscape of myeloma cells versus B-lymphoblastoid cells and B-cell acute lymphoblastic leukemia cell lines. E Volcano plot comparing glycoprotein LFQ intensity of four myeloma cell lines (replicate information listed above for C) to eight B-ALL cell lines (n = 3 biological replicates each). Significantly changed proteins colored in blue (log2-fold change > |1 | ; p < 0.05 by t-test). For B–E, source data in Supplementary Data 1.
